Cita APA (7a ed.)

Kusakabe, Y., Chiba, T., Oshima, M., Koide, S., Rizq, O., Aoyama, K., . . . Kato, N. (2021). EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma. Nature Portfolio.

Cita Chicago Style (17a ed.)

Kusakabe, Yuko, et al. EZH1/2 Inhibition Augments the Anti-tumor Effects of Sorafenib in Hepatocellular Carcinoma. Nature Portfolio, 2021.

Cita MLA (8a ed.)

Kusakabe, Yuko, et al. EZH1/2 Inhibition Augments the Anti-tumor Effects of Sorafenib in Hepatocellular Carcinoma. Nature Portfolio, 2021.